Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice

Vaccine

Volumn 29, Issue 34, 2011, Pages 5731-5739

  Nguyen, Chung Truong ^a,b   Kim, Soo Young ^a   Kim, Myoung Suk ^a   Lee, Shee Eun ^a,c   Rhee, Joon Haeng ^a,b  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Chonnam National University   (South Korea)

Author keywords

Flagellin; Pneumococcal vaccine; PspA

Indexed keywords

FLAGELLIN; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ANTIBODY; MEMBRANE PROTEIN; TETANUS TOXOID; TOLL LIKE RECEPTOR 5;

ARTICLE; BACTERIUM; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNIZATION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTECTION; PROTEIN DEGRADATION; SECRETIONS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; SURFACE PROPERTY; TETANUS; VIBRIO VULNIFICUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CELL LINE; FEMALE; FLAGELLIN; HEK293 CELLS; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RECOMBINANT FUSION PROTEINS; STREPTOCOCCUS PNEUMONIAE; VIBRIO VULNIFICUS;

EID: 79960554399     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.095     Document Type: Article

References (61)

1. Swartz M.N. Attacking the pneumococcus-a 100 years' war. N Engl J Med 2002, 346(10):722.
2. Giebink G. The prevention of pneumococcal disease in children. N Engl J Med 2001, 345:1177-1183.
3. WHO Pneumococcal vaccines. Weekly Epidemiol Record 2003, 14:110-119.
4. Madhi S.A., Petersen K., Madhi A., Wasas A., Klugman K.P. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000, 19(12):1141-1147.
5. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004, 19:353-363.
6. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 2004, 19:365-375.
7. Pelton S.I., Dagan R., Gaines B.M., Klugman K.P., Laufer D., O'Brien K., et al. Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003, 21(15):1562-1571.
8. Vesikari T., Wysocki J., Chevallier B., Karvonen A., Czajka H., Arsène J.-P., et al. Immunogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009, 28(4):S66-S76.
9. Yeh S.H., Gurtman A., Hurley D.C., Block S.L., Schwartz R.H., Patterson S., et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics 2010, 126(3):e493-e505.
10. CDC Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59(9):258-261.
11. Shinefield H.R.M., Black S.M., Ray P.M., Chang I.P., Lewis N.M., Fireman B.M., et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 1999, 18(9):757-763.
12. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
13. Robbins J.B., Austrian R., Lee C.J., Rastogi S., Schiffman G., et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983, 148(6):1136-1159.
14. Gray B.M., Dillon H.C. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis 1986, 5(2):201-207.
15. Byington C.L., Samore M.H., Stoddard G.J., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21-29.
16. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999, 17:S79-S84.
17. Briles D., Hollingshead S., King J., Swift A., Braun P., Park M., et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J Infect Dis 2000, 182(6):1694-1701.
18. McDaniel L.S., Swiatlo E. Pneumococcal disease: pathogenesis, treatment, and prevention. Infect Dis Clin Pract 2004, 12(2):93-98.
19. Feldman C., Munro N.C., Jeffery P.K., Mitchell T.J., Andrew P.W., Boulnois G.J., et al. Pneumolysin induces the salient histologic features of pneumococcal infection in the rat lung in vivo. Am J Resp Cell Mol Biol 1991, 5:416-423.
20. Lock R.A., Paton J.C., Hansman D. Purification and immunological characterization of neuraminidase produced by Streptococcus pneumoniae. Microb Pathog 1988, 5:461-467.
21. McDaniel L.S., Sheffield J.S., DeLucchi P., Briles D.E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun 1991, 59:222-228.
22. Rosenow C., Ryan P., Weiser J.N., Johnson S., Fontan P., Ortqvist A., et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997, 25:819-829.
23. Sampson J.S., O'Connor S.P., Stinson A.R., Tharpe J.A., Russel H. Cloning and nucleotide sequence analysis of psaA, the Streptococcus pneumoniae gene encoding a 37-kilodalton protein homologous to previously reported Streptococcus sp. adhesins. Infect Immun 1994, 64:319-324.
24. Kadioglu A., Weiser J.N., Paton J.C., Andrew P.W. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008, 6(4):288-301.
25. McDaniel L.S., Yother J., Vijayakumar M., McGarry L., Guild W.R., Briles D.E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med 1987, 165:381-394.
26. Jedrzejas M.J., Lamani E., Becker R.S. Characterization of selected strains of pneumococcal surface protein A. J Biol Chem 2001, 276(35):33121-33128.
27. Crain M.J., Waltman W.D., Turner J.S., Yother J., Talkington D.F., McDaniel L.S., et al. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun 1990, 58:3293-3299.
28. McDaniel L.S., Scott G., Kearney J.F., Briles D.E. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med 1984, 160:386-397.
29. McDaniel L.S., Scott G., Widenhofer K., Carroll J.M., Briles D.E. Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog 1986, 1(6):519-531.
30. He X., McDaniel L.S. The genetic background of Streptococcus pneumoniae affects protection in mice immunized with PspA 2007, Blackwell Publishing Ltd., p. 189-95.
31. Moreno A.T., Oliveira M.L.S., Ferreira D.M., Ho P.L., Darrieux M., Leite L.C.C., et al. Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clin Vaccine Immunol 2010, 17(3):439-446.
32. Kolberg J., Aase A., Michaelsen T.E., Rødal G. Epitope analyses of pneumococcal surface protein A: a combination of two monoclonal antibodies detects 94% of clinical isolates. FEMS Immunol Med Microbiol 2001, 31(3):175-180.
33. Briles D.E., Tart R.C., Swiatlo E., Dillard J.P., Smith P., Benton K.A., et al. Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA). Clin Microbiol Rev 1998, 11(4):645-657.
34. McDaniel L.S., Ralph B.A., McDaniel D.O., Briles D.E. Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microbial Pathog 1994, 17(5):323-337.
35. Tart R.C., McDaniel L.S., Ralph B.A., Briles D.E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis 1996, 173:380-386.
36. Bosarge J.R., Watt J.M., McDaniel D.O., Swiatlo E., McDaniel L.S. Genetic immunization with the region encoding the α-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae. Infect Immun 2001, 69(9):5456-5463.
37. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6(2):148-158.
38. Agrawal S., Agrawal A., Doughty B., Gerwitz A., Blenis J., Van Dyke T., et al. Cutting edge: different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol 2003, 171(10):4984-4989.
39. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(1):694-702.
40. Lee S., Koh Y., Kim M.-K., Kim Y., Kim S., Nam J., et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008, 28(2):157-165.
41. Applequist S.E., Rollman E., Wareing M.D., Liden M., Rozell B., Hinkula J., et al. Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005, 175(6):3882-3891.
42. Avery O.T., McLeod C.M., McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944, 79:137-158.
43. Briles D.E., Nahm M., Schroer K., Davie J., Baker P., Kearney J., et al. Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae. J Exp Med 1981, 183(3):694-705.
44. Kang H.Y., Srinivasan J., Curtiss R. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated salmonella enterica serovar typhimurium vaccine. Infect Immun 2002, 70(4):1739-1749.
45. Kolberg J., Aase A., Røal G., Littlejohn J.E., Jedrzejas M.J. Epitope mapping of pneumococcal surface protein A of strain Rx1 using monoclonal antibodies and molecular structure modelling. FEMS Immunol Med Microbiol 2003, 39(3):265-273.
46. Curtiss R.I., Zhang X., Wanda S.-Y., Kang H.Y., Konjufca V., Li Y., et al. Induction of host immune responses using Salmonella-vectored vaccines. Virulence mechanisms of bacterial pathogens 2007, 297-313. ASM Press, Washington, DC. 4th ed. K.A. Brogden, F.C. Minion, N. Cornick, T.B. Stanton, Q. Zhang, L.K. Nolan, M.J. Wannemuehler (Eds.).
47. Kim J.M., Oh Y.K., Kim Y.J., Cho S.J., Ahn M.H., Cho Y.J. Nuclear factor-kB plays a major role in the regulation of chemokine expression of HeLa cells in response to Toxoplasma gondii infection. Parasitol Res 2001, 87:758-763.
48. Mizel S.B., Honko A.N., Moors M.A., Smith P.S., West A.P. Induction of macrophage nitric oxide production by gram-negative flagellin involves signaling via heteromeric toll-like receptor 5/toll-like receptor 4 complexes. J Immunol 2003, 170(12):6217-6223.
49. Oma K., Zhao J., Ezoe H., Akeda Y., Koyama S., Ishii K.J., et al. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine 2009, 27(24):3181-3188.
50. Bättig P., Mühlemann K. Capsule genes of Streptococcus pneumoniae influence growth in vitro. FEMS Immunol Med Microbiol 2007, 50(3):324-329.
51. Reed L.J., Muench H. A simple method of estimating the fifty percent end points. Am J Epidemiol 1938, 27(3):493-497.
52. Portnoi M., Ling E., Feldman G., Dagan R., Mizrachi-Nebenzahl Y. The vaccine potential of Streptococcus pneumoniae surface lectin- and non-lectin proteins. Vaccine 2006, 24(11):1868-1873.
53. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53(282):457-481.
54. Ramos H.C., Rumbo M., Sirard J.-C. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. Trends Microbiol 2004, 12(11):509-517.
55. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410(6832):1099-1103.
56. Samatey F.A., Imada K., Nagashima S., Vonderviszt F., Kumasaka T., Yamamoto M., et al. Structure of the bacterial flagellar protofilament and implications for a switch for supercoiling. Nature 2001, 410(6826):331-337.
57. Smith K.D., Andersen-Nissen E., Hayashi F., Strobe K., Bergman M.A., Barrett S.L.R., et al. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol 2003, 4(12):1247-1253.
58. Le Moigne V., Robreau G., Mahana W. Flagellin as a good carrier and potent adjuvant for Th1 response: study of mice immune response to the p27 (Rv2108) Mycobacterium tuberculosis antigen. Mol Immunol 2008, 45(9):2499-2507.
59. Cuadros C., Lopez-Hernandez F.J., Dominguez A.L., McClelland M., Lustgarten J. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004, 72(5):2810-2816.
60. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(4):763-775.
61. Fukuyama Y., King J.D., Kataoka K., Kobayashi R., Gilbert R.S., Hollingshead S.K., et al. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice. J Immunol 2011, 186(4):2454-2461.